MSIDA, Malta, Oct. 05, 2017 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback